US Patent

US11273132 — Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Formulation · Assigned to Almirall LLC · Expires 2033-11-18 · 8y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects topical compositions containing dapsone and/or adapalene in a polymeric viscosity builder for treating various dermatological conditions.

USPTO Abstract

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Drugs covered by this patent

Patent Metadata

Patent number
US11273132
Jurisdiction
US
Classification
Formulation
Expires
2033-11-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Almirall LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.